Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Perminova, Olga A
NCT05269290: Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections	Completed	3	240	RoW	Ingavirin®, syrup, 30 mg/5 ml, Placebo	Valenta Pharm JSC	Influenza, Human, Acute Respiratory Infection, Common Cold	04/22	07/22
MMH-407-003, NCT04918771: Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old	Completed	3	435	RoW	Raphamin, Placebo	Materia Medica Holding	Acute Respiratory Viral Infection	07/23	07/23
NCT06379542: Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections	Recruiting	3	252	RoW	XC8, Placebo	Valenta Pharm JSC	Acute Respiratory Infection	12/25	12/25
NCT06715891: Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years	Recruiting	3	374	RoW	Raphamin, MMH-407, Placebo	Materia Medica Holding	Acute Respiratory Viral Infection	12/27	12/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Perminova, Olga A
NCT05269290: Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections	Completed	3	240	RoW	Ingavirin®, syrup, 30 mg/5 ml, Placebo	Valenta Pharm JSC	Influenza, Human, Acute Respiratory Infection, Common Cold	04/22	07/22
MMH-407-003, NCT04918771: Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old	Completed	3	435	RoW	Raphamin, Placebo	Materia Medica Holding	Acute Respiratory Viral Infection	07/23	07/23
NCT06379542: Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections	Recruiting	3	252	RoW	XC8, Placebo	Valenta Pharm JSC	Acute Respiratory Infection	12/25	12/25
NCT06715891: Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years	Recruiting	3	374	RoW	Raphamin, MMH-407, Placebo	Materia Medica Holding	Acute Respiratory Viral Infection	12/27	12/27